Clinical Trial Update: Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.

View source ↗

Summary

A real-world study assessing CDK4/6 inhibitors plus endocrine therapy and subsequent treatment in HR+/HER2- metastatic breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitors
• Endocrine therapy

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Breast Cancer, Endocrine Therapy | Status: RECRUITING